Moleculin Biotech
MBRXPhase 35300 Memorial Drive, Suite 950 |Houston, TX, 77007info@moleculin.com(713) 300-5160
Market Cap
$10.2M
Focus
Small Molecules
MBRX · Stock Price
USD 2.06661.69 (-99.69%)
Historical price data
About
5300 Memorial Drive, Suite 950 |Houston, TX, 77007info@moleculin.com(713) 300-5160
Pipeline Snapshot
88 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection... | Acute Myeloid Leukaemia (AML) | Phase 2/3 | |
| STAT3 Inhibitor WP1066 | Glioblastoma, IDH-Wildtype | Phase 2 | |
| Liposomal Annamycin | Leukemia, Myeloid, Acute | Phase 1/2 | |
| Liposomal Annamycin (L-Annamycin) | Sarcoma,Soft Tissue | Phase 1/2 | |
| Liposomal Annamycin | Leukemia, Myeloid, Acute | Phase 1/2 |
Funding History
3Total raised: $24.9M
Grant$2.9MCPRITAug 15, 2022
PIPE$10MUndisclosedSep 15, 2020
IPO$12MUndisclosedDec 15, 2016
Company Info
TypePublic
LocationUnited States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile